Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Asthma and Allergy"
DOI: 10.2147/jaa.s337284
Abstract: Background Masitinib is an oral tyrosine kinase inhibitor that selectively targets mast cell activity and platelet-derived growth factor receptor (PDGFR) signaling, both of which are implicated in various mechanisms of asthma pathogenesis. Objective Assessment of… read more here.
Keywords: placebo; masitinib; severe asthma; dependent severe ... See more keywords